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Porphyria cutanea tarda — a case report of severe course of 
disease in a female with alcohol addiction
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ABSTRACT
Porphyria cutanea tarda (PCT) belongs to the group of diseases with an increased incidence in the population of alcohol addicted people. 
Ethanol consumption has an influence on porphiryn metabolism which leads to disturbance in regulation of heme synthesis enzymes 
as well as direct damage of hepatocytes.
Porphyria is a disease which involves disturbance of hepatic heme synthesis enzymes. In the course of the PCT, porphyrines are ac-
cumulated in the skin and excreted with urine. The skin lesions occur during porphyrin disintegration caused by UV light. The clinical 
presentation of PCT is non-inflammatory blisters, occasionally accompanied by hemorrhage and eschar. Chronic skin damage may result 
in scarring and changes in pigmentation at the sites of blisters and milia. Other clinical symptoms include: arthritic pain of upper and 
lower extremities, dizziness, tinnitus, abdominal pain and sudden death.
We present extremely severe case of PCT in female, which was induced by sun exposure, hormone replacement therapy and alcohol intake.
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STRESZCZENIE
Porfiria skórna późna (PCT, porphyria cutanea tarda) należy do grupy chorób, których częstość występowania jest zwiększona u osób 
nadużywających alkoholu. Spożycie etanolu wpływa na metabolizm porfiryn, co prowadzi do zaburzeń regulacji enzymów biorących 
udział w syntezie hemu oraz bezpośrednio uszkadza hepatocyty. Porfiria jest chorobą związaną z zaburzeniem działania enzymów syntezy 
hemu w hepatocytach. W przebiegu PCT porfiryny są akumulowane w skórze, a także wydalane z moczem. Zmiany skórne pojawiają 
się podczas rozpadu porfiryn spowodowanego oddziaływaniem promieniowania UV. Do obrazu klinicznego PCT zalicza się: niezapalne 
pęcherze z towarzyszącym krwawieniem i strupami, ból stawów kończyn górnych i dolnych, zawroty głowy, szumy uszne, dolegliwości 
bólowe brzucha oraz nagłą śmierć. Przewlekłe uszkodzenie skóry doprowadza do bliznowacenia oraz zaburzeń pigmentacji. W niniejszej 
pracy zaprezentowano niezwykle ciężki przypadek PCT indukowany ekspozycją słoneczną, stosowaniem hormonalnej terapii zastępczej 
oraz nadużywaniem alkoholu.
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INTRODUCTION
The use of alcoholic beverages has been an integral part 
of many cultures for thousands of years. As shown by the 
most recent WHO data, globally, individuals above 15 years 
of age drink on average 6.2 litres of pure alcohol per year. 
The highest consumption levels continue to be found in 
the developed world, in particular in Eastern Europe and 
Northern Asia [1]. The harmful use of alcohol is a causal 
factor in more than 200 diseases and injury conditions [1].
The skin lesions seen in ethanol dependant individuals 
can be an early symptom of alcohol dependence. The most 
common skin lesions associated with ethanol usage are: ic-
terus, pruritus, hyperpigmentation, telangiectasias, capillary 
hemangiomas, caput medusa as well as palmar erythema. 
Furthermore, there are diseases that have been suggestive 
of alcohol dependence such as: recurrent bacterial skin 
infections, psoriasis, porphyria cutanea tarda (PCT), skin 
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granulomas, neoplasms of nasopharyngeal, liver, pancreas 
and skin [2].
PTC is a rare and very disfiguring disease which can be 
induced by ethanol [2]. Influence of ethanol on metabolism 
of the hepatocytes leads to accumulation of the photo-
sensitive porphyrines in the skin. Authors’ main goal is to 
educate caregivers of the alcohol dependent people about 
PCT. This is particularly important given the alarming data 
from the WHO report.
The porphyrias are a collection of enzyme deficiencies 
which lead to disturbance of heme production. PCT is the 
most common form of the porphyrias. The incidence of 
a disease is different in each region of the world. In Argen-
tine and the United States of America it is 1:25000, while 
in Sweden and Norway it is 1:10000 [3, 4]. It is claimed that 
Caucasian people are more vulnerable than others [5].
The disease is further divided into two subtypes: acqu-
ired and congenital. Type II PCT is inherited in an autosomal 
dominant mode. The defect leads to a reduction in the 
activity of uroporphyrinogen decarboxylase in all tissues [6].
First symptoms appear in sporadic form between the 
40–70th year of life. It is associated with liver damage which 
leads to uroporphyrinogen decarboxylase synthesis distur-
bance. Among factors that have been reported are: alcohol 
[3, 5, 7], drugs with estrogen-like potency, spironolactone, 
tamoxifen, highly active antiretroviral therapy and digoxin 
[3, 5, 7–10]. Autoimmune disorders and viruses such as HCV 
have also been associated with PCT [7, 11, 12].
The clinical presentation of PCT is non-inflammatory bli-
sters, sometimes accompanied by hemorrhage and eschar. 
Chronic skin damage may result in scarring and changes in 
pigmentation at the sites of blisters and milia. There is also 
an increase in the fragility of the skin, hirsutism and even 
scleroderma. Other clinical symptoms include arthritic pain 
of upper and lower extremities, dizziness, tinnitus, abdomi-
nal pain and sudden death [13, 14].
CASE DESCRIPTION
A 56-year-old Caucasian female presented to the Clinic 
of Dermatology in May 2013 with mucosal and skin changes 
located on hand, face, neck and limbs (Fig. 1, 2). Seven weeks 
prior to hospitalization inflamed skin lesions were visible on 
the nasal mucosa and the nasal bridge. Later, hemorrhagic 
erosions appeared on the chest, limbs and on the dorsal 
aspect of the hands. These changes were later covered by 
eschar. Additionally pruritus and oedema of the face and 
limbs were present. The patient suffered from severe arth-
ritis, dizziness and unilateral tinnitus. Past medical history 
included hypertension diagnosed 6 years earlier, suspicion 
of glucose intolerance, hypercholesterolemia. Additional-
ly, the patient had hysterectomy at the age of 43 due to 
fibroids. The preexisting medication included metformin, 
indapamide, simvastatin, aspirin, pantoprazole, estradiol.
Laboratory tests revealed hypokalemia, hyponatremia, 
low RBC count (3.35 T/L), macrocytic anemia (Hb: 10,7 g/dL; 
MCV: 104 fL), decreased hematocrit (31.0 %), hypoalbumi-
nemia (33.4 g/L), decreased APTT, increased fibrinogen, 
leukocytosis (13.66 G/L) and a slight rise in C Reactive Protein 
(CRP levels 26.6 mg/dL). The renal, liver and iron studies 
were normal. Ultrasonographic imaging of the left kidney 
demonstrated the presence of a single layer of parenchymal 
fibrosis in hyperechogenic bands, presumably inflammatory 
changes. Chest X-ray was normal. At this point, all previous 
medications were discontinued, including the anti-hyper-
tensives.
Before admission to the Clinic, patient was treated as 
an acute solar urticaria without effect.
Prior to the onset of the symptoms the patient had sun 
exposure as well as an alcohol abuse episode that lasted 
for about a week. Contact with the patient was difficult, she 
was demanding and very irritable. During hospitalization, 
Figure 1. Skin lesions typical of PCT which are present at the 
beginning of therapy in the Clinic. Necrotic tissues covered by 
hemorrhagic scabs were observed
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the patient did not agree to psychiatric consultation. The 
information about patient’s alcohol abuse was given by 
her family. There was no presence of withdrawal symptoms 
during hospitalization in the Clinic.
Alcohol consumption and estrogens were responsible 
for enzyme deficiency, UV exposition due to presence of 
skin lesion.
Diagnosis of PCT was based on the result of clinical exa-
mination, histopathological findings as well as a laboratory 
studies specific to porphyrias [15].
Laboratory studies specific to porphyrias showed in-
creased uroporphyrin, porphyrin and coproporphyrin in 
the urine. The levels of porphyrin 6-COOH, 5-COOH, Del-
ta-aminolevulinic acid and porphobilinogen were within 
normal ranges. The porphyrin fluorescent spectrum test of 
the plasma was normal.
The histopathological examination of the skin showed 
typical PCT changes [15]. Epidermis was described as smo-
oth and slightly thickened. There was also the evidence 
of homogenization of the basal epidermis, slight increase 
in dermal vascularity surrounded by sparse inflammatory 
infiltration. Immunological studies of the deposits around 
the vessels showed the presence of IgA, IgM and C3c in the 
walls of superficial vascular plexuses.
Further diagnostics included exclusion of vasculitis, SLA 
and scleroderma. The petechial changes on the chest and 
limbs along with the mucosal erosions led to immunological 
testing to rule out vasculitis and systemic lupus erythema-
tosus. The results were as follows: Anti-p/Nuclear Hep2 ANA 
1:160, PM-Scl positive and anti-p granulocyte, ANCA, cry-
oglobulins and circulating immune complexes C1q and C3d 
were negative. Consultation with a laryngologist excluded 
granulomatous disease. HCV infection was excluded in la-
boratory tests. Patient was vaccinated against HBV. 
There was no history of smoking, usage of causative 
drugs, except for estrogens.
Treatment with hydroxychloroquine 200 mg daily was 
started with further reduction of dose to 200 mg twice 
a week after clinical improvement. After gynecological con-
sultation, the patient was allowed to resume treatment with 
estradiol. The patient was encouraged to begin the proper 
therapy. Moreover, avoidance of UV exposure was empha-
sized. Additional treatment included: cetirizine, hydroxyzine, 
duloxetine and topical treatment: steroid ointment, mupi-
rocinum 2%, chloramphenicol, octenidine, Cicalfate (Avene 
Thermal Spring Water, caprylic; mineral oil; zinc oxide; alu-
minium sucrose octasulfate; aluminium stearate; beeswax; 
copper sulfate; magnesium stearate). Despite the intensive 
treatment the heeling of the skin lesions, especially those 
located on the limbs, was very slow. The patient also received 
diaminodiphenyl sulfone 500 mg, pentoxifylline 0.1–0.3 g, 
amoxicillin with clavulanic acid 1.2 GX3 i.v. and vitamin 
B12 1000 mcg i.m. to intensify the treatment.
After worsening of anemia symptoms, a hematological 
consultation was conducted. A thorough anemia diagnosis 
was made and it revealed low cobalamin levels. The hema-
tologist added prednisone 25 mg and folic acid 15 mg daily 
for the macrocytic anemia.
Figure 2. Skin status before as well as after the treatment. Massive necrotic skin lesions covered by scabs. Irreversible scars and 
hyperpigmentations of the skin in the area of shins
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With the additional treatment there was a normalization 
of the morphological parameters in the blood count. The 
cutaneous lesions gradually disappeared, no formation of 
new lesions was observed (Fig. 2). The treatment with Hydro-
xychloroquine was finalized after 6 months. Unfortunately, 
severe scarring was seen after complete wound healing.
DISCUSSION
Our patient report is an example of multiple inducing fac-
tors that revealed an acquired form of porphyria cutanea tarda.
Alcohol is metabolized in hepatic microsomal oxidi-
zing system and ethanol consumption has an influence on 
porphiryn metabolism [16]. It leads to disturbance in the 
regulation of heme synthesis enzymes as well as direct he-
patocyte damage. Those factors can trigger acute or chronic 
hepatic disease [16]. Disturbances in oxidation-reduction 
reactions are present in alcohol elimination process. It is 
acknowledged as a main liver damaging factor [17]. 
The most common susceptibility factor for PCT is etha-
nol use. It was revealed in Jalil cohort study in 2010 that in 
the group of 143 patients alcohol consumption was obse-
rved in 87% of cases [5]. Results of the research prepared 
in Wroclaw, Poland showed that ethanol usage and HCV 
infection were two main PCT etiological factors [14]. Pri-
marily, it was claimed that fully symptomatic PCT appears 
only in heavy drinkers. Later, it was revealed that regular 
consumption of even small amount of alcohol can lead to 
the manifestation of PCT [18]. Alcohol interacts with heme 
production enzymes in healthy people and those with bio-
chemical and clinical symptoms of porphyria. After alcohol 
consumption, in patients with asymptomatic coproporphy-
rinuria, it can become constitutive while alcohol liver dam-
age will be present. Ethanol is able to convert asymptomatic 
coproporphyrinuria into fully symptomatic PCT [16].
Alcohol is the most important inducing and aggravating 
factor of PCT [5, 16]. Alcohol abstinence must be included 
into patient’s treatment plan. It can be a cause of long and 
turbulent course of the disease as in the above mentioned 
case. In the study by Jalil, most patients (90%) had 2 or more 
susceptibility factors [5]. For that reason it is important to 
ask patients about all probable triggering factors. 
Estrogen therapy is the predominant risk factor in 
women (oral contraception pills and hormone replacement 
therapy). It has been stated that estrogen therapy may pro-
voke PCT in up to 40% of women with acquired PCT [15]. The 
estrogens intake was present in 71% of patients researched 
by Jalil [5]. Our patient was under estrogen therapy due to 
the previous hysterectomy.
Skin changes that appeared after a week of intensive 
sun exposure were the main reason why the patient was 
seeking medical help [2]. 
There are two standard therapies of PCT: phlebotomy 
400–500 mL every 2 weeks until serum ferritin levels fall to 
20 ng/mL or a low-dose antimalarial therapy. A drug typi-
cally used is hydroxychloroquine — 100 mg twice a week 
or chloroquine 125 mg twice a week [19]. According to the 
current guidelines, the patient was treated with anti-malarial 
drugs. The treatment of PCT additionally consists in avoid-
ance of triggering factors.
In randomized controlled trials, it was proved that hydro-
xychloroquine is as effective as phlebotomy in the treatment 
of a group of 48 patients. About 6 months of therapy were 
needed to receive a good response. There was no significant 
difference in efficacy between phlebotomy therapy and 
hydroxychloroquine. Using antimalarial drugs has better 
compliance among patients, is cheaper and has lower risk 
of hepatitis and HIV infection [20]. Antimalarial drug the-
rapy was chosen for our patient because of the presence 
of anemia, good influence on insulin resistance and high 
compliance of the treatment.
There are some novel methods of treatment of PCT. It is 
reported that refractory blisters can be successfully treated 
with pimecrolimus as an adjuvant to hydroxychloroquine 
[21]. Anemia may preclude phlebotomy. Iron chelating 
agents as Desferrioxamine and Deferasirox can be used 
as an alternative to phlebotomy [22, 23]. There was a good 
result of hydroxychloroquine treatment.
CONCLUSIONS
It is important to consider PCT in differentiation diagno-
sis of the skin lesions in group of alcohol usage patients. Only 
early medical intervention can prevent long term treatment 
and disfiguration.
Diagnosis of PCT should obligate doctor to ask questions 
about amount of alcohol intake and signs of addiction.
Presence of PCT can be the first symptom of liver da-
mage [18].
Every diagnosed case of PCT should be carefully exa-
mined for coexisting risk factors such as cirrhosis hepatis 
and/or liver cancer [24]. 
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